Brief: Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
15/09/2021 13:18
Sept 15 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED'S PHASE 2 ORAL INSULIN NASH TRIAL REACHES OVER 50%
ENROLLMENT
Source text for Eikon: ID:nPn9nBDlfa
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results